Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P.

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q2 2025 investor letter. A copy of the letter can be ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...